5,293 results match your criteria Narcolepsy


Demographic and nap-related variance of the MSLT: results from 2,498 suspected hypersomnia patients: Clinical MSLT variance.

Sleep Med 2018 Dec 30;55:115-123. Epub 2018 Dec 30.

SleepMed, Inc. Columbia, SC, USA; The University of South Carolina Medical School, Columbia, SC, USA; Bogan Sleep Consultants, LLC, Columbia, SC, USA.

Objective: The purpose of this study was to enhance our understanding of clinical trends in sleep and rapid eye movement (REM) propensity on the multiple sleep latency test (MSLT). Demographic variables of interest included early childhood/advanced age, gender, race, and REM-suppressant use.

Methods: Nocturnal sleep studies and 5-nap MSLTs were retrieved from a large repository of deidentified studies from various US sleep clinics between 2007 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sleep.2018.12.013DOI Listing
December 2018

CD8 T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens.

Nat Commun 2019 Feb 19;10(1):837. Epub 2019 Feb 19.

Department of Clinical Biochemistry, Molecular Sleep Laboratory, Rigshospitalet, 2600 Glostrup, Denmark.

Narcolepsy Type 1 (NT1) is a neurological sleep disorder, characterized by the loss of hypocretin/orexin signaling in the brain. Genetic, epidemiological and experimental data support the hypothesis that NT1 is a T-cell-mediated autoimmune disease targeting the hypocretin producing neurons. While autoreactive CD4 T cells have been detected in patients, CD8 T cells have only been examined to a minor extent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-08774-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381094PMC
February 2019
1 Read

Finding a needle in the haystack-narcolepsy and obstructive sleep apnea.

Sleep Breath 2019 Feb 18. Epub 2019 Feb 18.

Departamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo, Rua Napoleão de Barros, 925 - 2° andar, Vila Clementino, São Paulo, 04024-002, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11325-019-01800-yDOI Listing
February 2019

A four year experience in narcolepsy from a sleep clinic at a tertiary care centre with a short review of contemporary Indian literature.

Indian J Med Res 2018 Dec;148(6):748-751

Department of Internal Medicine, All India Institute of Medical Sciences, New Delhi, India.

Narcolepsy is a common sleep disorder in Western countries but rarely reported from India. Here, we report a small case series of four narcolepsy patients seen over a four year period in the sleep clinic of a tertiary care hospital in north India. The diagnosis was established by clinical history and two or more sleep-onset rapid eye movements (SOREMs) on multiple sleep latency tests (MSLTs) following overnight polysomnography (PSG). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijmr.IJMR_888_16DOI Listing
December 2018

Pitolisant and intravenous cocaine self-administration in mice.

Eur J Pharmacol 2019 Feb 13. Epub 2019 Feb 13.

Département de Psychologie, Cognition et Comportement, Université de Liège, Place des Orateurs, 2/B-32, Liège, Belgium.

Pitolisant, a selective inverse agonist for the histamine H3 receptor, is a new treatment for adults suffering from narcolepsy. Numerous studies have shown that striatal H3 receptors can modulate the activity of the dopamine mesolimbic system, a pathway that plays a crucial role in drug addiction. Therefore, it is important to guarantee that pitolisant has no abuse potential and does not potentiate the behavioral effects of psychostimulants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2019.02.019DOI Listing
February 2019

Use and safety of nitrous oxide during lumbar puncture for the diagnosis of childhood narcolepsy.

Sleep Med 2018 Dec 18. Epub 2018 Dec 18.

IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sleep.2018.12.003DOI Listing
December 2018
1 Read

Oral L-Carnitine used to treat narcoleptic type 1 patient during pregnancy - A case report.

Sleep Sci 2018 Jul-Aug;11(4):215-216

UNIFESP, Neurologia e Neurocirurgia - São Paulo - São Paulo - Brazil.

Narcolepsy type 1 is a sleep disorder characterized by excessive daytime sleepiness (EDS), sleep fragmentation, hypnagogic hallucinations, sleep paralysis, and cataplexy. Stimulant medications such as modafinil and amphetamines are the first-line medications for treating sleepiness. However, the management of narcolepsy during special circumstances of life such as pregnancy is complex. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5935/1984-0063.20180035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361304PMC
February 2019
1 Read

Night Stepping: Fitbit Cracks the Case.

J Clin Sleep Med 2019 Feb 4. Epub 2019 Feb 4.

Abstract: The most common sleep disorders that can result in injurious or violent behaviors include REM sleep behavioral disorder, sleepwalking, comorbid parasomnias, sleep-related dissociative disorder, and obstructive sleep apnea. Video polysomnography is usually indicated to evaluate recurring sleep-related injury in adults. Only one-third of patients with complex paroxysmal nocturnal events will have one of their habitual events on a single night of in-laboratory video polysomnography, most often those who have prominent, high-frequency motor features. Read More

View Article

Download full-text PDF

Source
February 2019
5 Reads

Maintenance of Wakefulness Test, real and simulated driving in patients with narcolepsy/hypersomnia.

Sleep Med 2018 Mar 8;55:1-5. Epub 2018 Mar 8.

Université de Bordeaux, Sommeil, Attention et Neuropsychiatrie, USR 3413, Bordeaux, France; CNRS, SANPSY, USR 3413, Bordeaux, France; CHU Bordeaux, Centre Hypersomnies Rares, Bordeaux, France. Electronic address:

Study Objectives: To assess the relationship between real and simulated driving performance and the objective level of alertness as measured by the Maintenance of Wakefulness Test (MWT) in patients suffering from narcolepsy or idiopathic hypersomnia.

Methods: Twenty-seven patients (10 patients with narcolepsy, type 1 (n = 7) and type 2 (n = 3), and 17 patients with idiopathic hypersomnia, mean age = 33.8 ± 11. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sleep.2018.02.009DOI Listing
March 2018
1 Read

Assessing readiness to drive in adolescents with narcolepsy: what are providers doing?

Sleep Breath 2019 Feb 8. Epub 2019 Feb 8.

Division of Pulmonary and Sleep Medicine, Children's Mercy Hospital, 2401 Gillham Rd, Kansas City, MO, 64108, USA.

Purpose: There are no universally accepted guidelines for assessing driving readiness in adolescents with narcolepsy. The purpose of the present study was to survey pediatric sleep medicine providers regarding their current practice patterns for assessing driving readiness in adolescents with narcolepsy, knowledge of their state laws regarding physician reporting of unsafe drivers, and opinions regarding what physician duty ought to be.

Methods: This was an anonymous web-based survey distributed via the PedSleep listserv, which serves as a hub of communication for pediatric sleep medicine providers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11325-019-01799-2DOI Listing
February 2019
1 Read

Restless legs syndrome and iron deficiency in adults with attention deficit hyperactivity disorder.

Sleep 2019 Feb 5. Epub 2019 Feb 5.

National Reference Network for Narcolepsy, Department of Neurology, Hôpital Gui-de-Chauliac, CHU Montpellier, France.

Objective: The association between restless legs syndrome (RLS), periodic leg movements during sleep (PLMS) and iron deficiency has been reported in children with attention deficit/hyperactivity disorder (ADHD); however little is known in adults. The aim of this study was to assess frequencies of RLS, PLMS and other leg movements (LM) and iron deficiency and their relationships with ADHD phenotype in adults with ADHD.

Methods: 200 adults with ADHD (112 males, median age 31 years) were evaluated on lifetime ADHD symptoms and sleep characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/sleep/zsz027DOI Listing
February 2019
2 Reads

Pandemrix-induced narcolepsy is associated with genes related to immunity and neuronal survival.

EBioMedicine 2019 Jan 30. Epub 2019 Jan 30.

Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

Background: The incidence of narcolepsy rose sharply after the swine influenza A (H1N1) vaccination campaign with Pandemrix. Narcolepsy is an immune-related disorder with excessive daytime sleepiness. The most frequent form is strongly associated with HLA-DQB1*06:02, but only a minority of carriers develop narcolepsy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523964193004
Publisher Site
http://dx.doi.org/10.1016/j.ebiom.2019.01.041DOI Listing
January 2019
5 Reads

A population-based and case-controlled study of children and adolescents with narcolepsy: Health-related quality of life, adaptive behavior and parental stress.

Eur J Paediatr Neurol 2019 Jan 19. Epub 2019 Jan 19.

Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Objective: To investigate health-related quality of life (HrQoL) and adaptive behavior in young people with narcolepsy and stress among their parents.

Methods: In a cross-sectional exploratory quantitative study design, 37 young people with narcolepsy (8-20 years of age) and their parents were recruited. Thirty-one had post-H1N1 vaccination-related narcolepsy (PHV) and six had narcolepsy not related to PHV (nPHV). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpn.2019.01.004DOI Listing
January 2019
2 Reads

A Randomized Study of Solriamfetol for Excessive Sleepiness in Narcolepsy.

Ann Neurol 2019 Jan 29. Epub 2019 Jan 29.

Reference National Center for Narcolepsy-Hypersomnia, Gui-de-Chauliac Hospital, CHU Montpellier, INSERM U1061, France.

Objective: Solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor with wake-promoting effects. This phase 3 study (NCT02348593) evaluated the safety and efficacy of solriamfetol in narcolepsy.

Methods: Patients with narcolepsy with mean sleep latency <25 minutes on the Maintenance of Wakefulness Test (MWT), Epworth Sleepiness Scale (ESS) score ≥10, and usual nightly sleep ≥6 hours were randomized to solriamfetol 75, 150, or 300 mg, or placebo for 12 weeks. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ana.25423
Publisher Site
http://dx.doi.org/10.1002/ana.25423DOI Listing
January 2019
5 Reads

Temporal Course of Cerebral Autoregulation in Patients With Narcolepsy Type 1: Two Case Reports.

Front Neurol 2018 10;9:1155. Epub 2019 Jan 10.

Clinical Trial and Research Center for Stroke, Department of Neurology, The First Hospital of Jilin University, Changchun, China.

Cerebral autoregulation is the mechanism by which constant cerebral blood flow is maintained despite changes in arterial blood pressure. In the two presented cases, cerebral autoregulation was impaired in patients with narcolepsy type 1, and both venlafaxine and fluoxetine may have the potential to improve the impaired cerebral autoregulation. A relationship may exist between impaired cerebral autoregulation and neurological symptoms in patients with narcolepsy type 1. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fneur.2018.01155
Publisher Site
http://dx.doi.org/10.3389/fneur.2018.01155DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337715PMC
January 2019
4 Reads

Adherence to CPAP: What Should We Be Aiming For, and How Can We Get There?

Chest 2019 Jan 23. Epub 2019 Jan 23.

National Jewish Health, Denver, CO.

The purpose of this review was to summarize what is currently known regarding two important questions facing the field of sleep medicine today: (1) How many hours of CPAP use per night are necessary to improve daytime symptoms and reduce cardiovascular risk associated with OSA?; and (2) What strategies could be implemented to optimize adherence in clinical settings? Despite the widespread adoption of a threshold approach to CPAP management, the literature to date suggests a dose-response relationship between CPAP usage and a range of outcomes, including sleepiness, functional status, and BP; the data also suggest that the optimal adherence level differs depending on the outcome in question. Over the years, psychological measures of behavior change constructs have been increasingly recognized as the most consistent predictors of CPAP adherence, and, as such, the most successful interventions for optimizing adherence have been behavioral in nature. Unfortunately, behavioral therapies have not been translated from highly controlled research settings to comparative-effectiveness studies and finally into routine care, mainly due to feasibility and cost issues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chest.2019.01.012DOI Listing
January 2019
3 Reads

HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy.

Sci Rep 2019 Jan 24;9(1):477. Epub 2019 Jan 24.

Sleep and circadian neurobiology laboratory, School of Medicine, Stanford University, Stanford, USA.

Narcolepsy is a chronic sleep disorder caused by a loss of hypocretin (hcrt) neurons in the hypothalamus. Cerebrospinal fluid (CSF) hcrt-1 measurement has been well established as a gold standard of narcolepsy diagnosis, although some portions of narcoleptic patients show normal hcrt-1 levels. We aimed to examine peptide degradation of hcrt-1 and its abnormality in the CSF of patients by using high performance liquid chromatography (HPLC) followed by radioimmunoassay (RIA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-36942-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346108PMC
January 2019
1 Read

Health-Related Quality of Life in Patients With Narcolepsy: A Review of the Literature.

J Nerv Ment Dis 2019 Feb;207(2):84-99

Unit of Neurology I.C., Oasi Institute for Research on Mental Retardation and Brain Aging (IRCCS), Troina, Italy.

Narcolepsy is a chronic disorder characterized by symptoms of excessive daytime sleepiness, irresistible sleep attacks that may be accompanied by cataplexy brought on by emotions, sleep paralysis, and hypnagogic hallucinations. This is a review of 32 empirical articles on health-related quality of life (HRQoL) published in peer-reviewed journals over the past 37 years. Deleterious implications on education, recreation, driving, sexual life, and personality are associated with the disease with a consequent negative psychosocial impact. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/NMD.0000000000000918DOI Listing
February 2019
1 Read

The development of hypocretin deficiency in narcolepsy type 1 can be swift and closely linked to symptom onset: clues from a singular case.

Sleep 2019 Jan 21. Epub 2019 Jan 21.

Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/sleep/zsz009DOI Listing
January 2019
2 Reads

Prospective memory in narcolepsy type 1 patients.

J Psychosom Res 2019 Feb 21;117:30-31. Epub 2018 Dec 21.

Université Paris Descartes, APHP, Hôtel Dieu, Centre du Sommeil et de la Vigilance, Centre de référence hypersomnies rares et, EA 7330 Vifasom, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpsychores.2018.12.008DOI Listing
February 2019
1 Read

Diagnostic Criteria, Differential Diagnosis, and Treatment of Minor Motor Activity and Less Well-Known Movement Disorders of Sleep.

Curr Treat Options Neurol 2019 Jan 19;21(1). Epub 2019 Jan 19.

Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.

Purpose Of Review: Sleep-related movement disorders (SRMD) include several different motor activities during sleep. Few of them are well known and well classified, whereas others are minor motor disorders of sleep which are neither thoroughly characterized and classified nor have been extensively investigated to clarify their pathogenesis and clinical relevance. This review will focus on those minor sleep-related movement disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11940-019-0543-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339673PMC
January 2019
2 Reads

Use of cognitive enhancers: methylphenidate and analogs.

Eur Rev Med Pharmacol Sci 2019 Jan;23(1):3-15

Unit of Forensic Toxicology, Sapienza University of Rome, Rome, Italy.

Objective: In the last decades, several cognitive-enhancing drugs have been sold onto the drug market. Methylphenidate and analogs represent a sub-class of these new psychoactive substances (NPS). We aimed to review the use and misuse of methylphenidate and analogs, and the risk associated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_201901_16741DOI Listing
January 2019
2 Reads

Confirmatory factor analysis of the SLEEP-50 Questionnaire in Trichotillomania (Hair-Pulling Disorder) and Excoriation (Skin-Picking) Disorder.

Psychiatry Res 2019 Jan 7;273:197-205. Epub 2019 Jan 7.

Division of Child and Adolescent Psychiatry, University of California, Los Angeles, CA, USA.

The study objective was to perform a confirmatory factor analysis of the SLEEP-50 Questionnaire (SLEEP-50) in Trichotillomania (Hair-Pulling Disorder) and Excoriation (Skin-Picking) Disorder and compare sleep complaints in adults with Trichotillomania, Excoriation Disorder and non-affected controls. Participants were 234 adults with Trichotillomania, 170 with Excoriation Disorder, and 146 non-affected controls. Participants rated sleep using the SLEEP-50 and Pittsburgh Sleep Quality Index (PSQI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psychres.2019.01.022DOI Listing
January 2019
2 Reads

Genetics of narcolepsy.

Hum Genome Var 2019 8;6. Epub 2019 Jan 8.

2Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Narcolepsy is a term that was initially coined by Gélineáu in 1880 and is a chronic neurological sleep disorder that manifests as a difficulty in maintaining wakefulness and sleep for long periods. Currently, narcolepsy is subdivided into two types according to the International Classification of Sleep Disorders, 3rd edition: narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). NT1 is characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep paralysis and is caused by a marked reduction in neurons in the hypothalamus that produce orexin (hypocretin), which is a wakefulness-associated neuropeptide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41439-018-0033-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325123PMC
January 2019
2 Reads

Psychiatric symptoms in patients with post-H1N1 narcolepsy type 1 in Norway.

Sleep 2019 Jan 12. Epub 2019 Jan 12.

Norwegian Centre of Expertise for Neurodevelopmental Disorders and Hypersomnias, Department of Rare Disorders and Disabilities, Oslo University Hospital, Norway.

Study Objectives: Several studies have reported psychiatric comorbidity in patients with narcolepsy type 1 (NC1). The primary aim of this study was to explore the extent of psychiatric symptoms in a cohort of Norwegian NC1 patients, most of whom were H1N1-vaccinated. We also wanted to explore possible causes of the psychiatric symptoms seen in NC1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/sleep/zsz008DOI Listing
January 2019
1 Read

The neuronal network of laughing in young patients with untreated narcolepsy.

Neurology 2019 Jan 11. Epub 2019 Jan 11.

From the Department of Medicine and Surgery (A.E.V.), Sleep Medicine Center, University of Parma; Department of Biomedical, Metabolic, and Neural Science (A.E.V., S.M.) and Center for Neuroscience and Neurotechnology (A.E.V., S.M.), University of Modena and Reggio Emilia; Department of Biomedical and Neuromotor Sciences (F.P., G.P.), University of Bologna; IRCCS Istituto Delle Scienze Neurologiche (F.P., G.P.), AUSL di Bologna; and Neurology Unit (F.T., S.M.), OCSAE Azienda Ospedaliero-Universitaria, Modena, Italy.

Objective: To investigate the neuronal correlates of spontaneous laughter in drug-naive pediatric patients with narcolepsy type I (NT1) compared to healthy controls by means of blood oxygen level-dependent (BOLD) MRI.

Methods: Twenty-one children/adolescents with recent onset of NT1 and 21 age- and sex-matched healthy controls were studied with fMRI while viewing funny videos using a naturalistic paradigm. Whole-brain hemodynamic correlates of spontaneous laughter were investigated in each group and compared by use of appropriate second-level general linear model analyses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006853DOI Listing
January 2019
14 Reads

Exploration of autonomic activity in narcolepsy: The riddle remains unsolved.

Clin Neurophysiol 2019 Mar 27;130(3):406-407. Epub 2018 Dec 27.

Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinph.2018.12.004DOI Listing
March 2019
3 Reads

A Phase I, Randomized, Crossover, Open-Label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food.

Clin Ther 2018 Dec 28. Epub 2018 Dec 28.

Jazz Pharmaceuticals, Palo Alto, CA, United States.

Purpose: Solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects, is currently being evaluated for the reduction of sleepiness and improvement of wakefulness in patients with narcolepsy and obstructive sleep apnea. The purpose of this study was to evaluate the effect of food on the pharmacokinetic (PK) parameters and bioavailability of solriamfetol at the highest intended therapeutic dose in healthy adults and to characterize its renal excretion under fasting conditions.

Methods: In this open-label, randomized, crossover study, healthy adult subjects received a single 300-mg dose of solriamfetol in a fasted condition (10 h) and in a fed condition (30 min after the start of a standardized high-fat, high-calorie breakfast), with at least a 7-day washout period between doses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2018.12.001DOI Listing
December 2018
2 Reads

Management of Excessive Daytime Sleepiness in Narcolepsy With Baclofen.

Pediatr Neurol 2018 Nov 22. Epub 2018 Nov 22.

Pediatric Neurology Service Line for Northwell Health, Department of Pediatrics & Neurology, Zucker School of Medicine at Hofstra/Northwell, Cohen Children's Medical Center, Lake Success, New York; Division of Pediatric Neurology, Department of Pediatrics, Cohen Children's Medical Center, Lake Success, New York; Pediatric Sleep Program (Neurology), Department of Pediatrics, Cohen Children's Medical Center, Lake Success, New York. Electronic address:

Background: Narcolepsy is a disabling sleep-wake disorder characterized by the pentad symptoms of excessive daytime sleepiness, sleep paralysis, sleep fragmentation, sleep-related hallucinations, and cataplexy. There is no curative therapy for narcolepsy. Treatment is therefore symptom directed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pediatrneurol.2018.10.020DOI Listing
November 2018
2 Reads

Important decisions in choosing the pharmacotherapy for narcoleptics.

Expert Opin Pharmacother 2018 Dec 28:1-4. Epub 2018 Dec 28.

a Neurology Unit, Department of Neurosciences , University Hospital of Udine , Udine , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1561861DOI Listing
December 2018
2 Reads

Sleep disorders in patients with ADHD: impact and management challenges.

Nat Sci Sleep 2018 14;10:453-480. Epub 2018 Dec 14.

Department of Psychiatry, Faculty of Medicine, McGill University, Montréal, Quebec, Canada,

Attention deficit/hyperactivity disorder (ADHD) is one of the most commonly diagnosed disorders in childhood, enduring through adolescence and adulthood and presenting with symptoms of inattention, hyperactivity, and/or impulsivity and significantly impairing functioning. Primary sleep disorders such as sleep-disordered breathing, restless leg syndrome, circadian rhythm sleep disorder, insomnia, and narcolepsy are commonly comorbid in these individuals but not often assessed and are therefore often left untreated. Sleep disturbances in individuals with ADHD can result in significant functional impairments that affect mood, attention, behavior, and ultimately school/work performance and quality of life. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/sleep-disorders-in-patients-with-a
Publisher Site
http://dx.doi.org/10.2147/NSS.S163074DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299464PMC
December 2018
7 Reads

Narcolepsy and emotional experience: a review of the literature.

Behav Brain Funct 2018 Dec 26;14(1):19. Epub 2018 Dec 26.

Department of Psychology, University of Rome "Sapienza", Via dei Marsi, 78, 00185, Rome, Italy.

Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep paralysis. This disease affects significantly the overall patient functioning, interfering with social, work, and affective life. Some symptoms of narcolepsy depend on emotional stimuli; for instance, cataplectic attacks can be triggered by emotional inputs such as laughing, joking, a pleasant surprise, and also anger. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12993-018-0151-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305999PMC
December 2018
3 Reads

Narcolepsy and 2009 H1N1 pandemic vaccination in Taiwan.

Sleep Med 2018 Nov 26. Epub 2018 Nov 26.

Taiwan Centers for Disease Control, Taipei, Taiwan.

Background: Several European countries have observed an association between narcolepsy and H1N1 vaccines containing AS03 adjuvant in children/adolescents. In Taiwan, a nationwide campaign starting November 2009 administered H1N1 vaccines without adjuvant or with MF59 adjuvant to 67% of children and 12% of adults.

Methods: For those registered in the 2000-2012 National Health Insurance (NHI) databases, we compared age-stratified (0-4, 5-18, 19-59, and ≥60 years) incidence of first referral for a diagnostic MSLT for the pre-pandemic, pandemic/pre-vaccination, and vaccination/post-pandemic period. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13899457183056
Publisher Site
http://dx.doi.org/10.1016/j.sleep.2018.10.036DOI Listing
November 2018
9 Reads

Unexpected Fat Distribution in Adolescents With Narcolepsy.

Front Endocrinol (Lausanne) 2018 6;9:728. Epub 2018 Dec 6.

Department of Medical and Health Sciences (IMH), Linköping University, Linköping, Sweden.

Narcolepsy type 1 is a chronic sleep disorder with significantly higher BMI reported in more than 50% of adolescent patients, putting them at a higher risk for metabolic syndrome in adulthood. Although well-documented, the body fat distribution and mechanisms behind weight gain in narcolepsy are still not fully understood but may be related to the loss of orexin associated with the disease. Orexin has been linked to the regulation of brown adipose tissue (BAT), a metabolically active fat involved in energy homeostasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2018.00728DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292486PMC
December 2018
1 Read

Exploration of cardiac sympathetic adrenergic nerve activity in narcolepsy.

Clin Neurophysiol 2019 Mar 6;130(3):412-418. Epub 2018 Dec 6.

Sleep-Wake Disorders Centre, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, France; National Reference Network for Narcolepsy, CHU Montpellier, France; INSERM, U1061, Neuropsychiatrie, Recherche Clinique et Epidémiologique, Univ. Montpellier, Montpellier, France. Electronic address:

Objective: To compare cardiac sympathetic adrenergic nerve activity in patients with narcolepsy type 1 (NT1) and controls using I-MIBG myocardial scintigraphy, and to determine the clinical and neurophysiological variables associated with I-MIBG scintigraphy results in NT1.

Methods: Fifty-six NT1 patients and 91 controls without neurological diseases underwent a cardiac scintigraphy. MIBG uptake was quantified by delayed heart/mediastinum (H/M) ratio. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinph.2018.11.014DOI Listing
March 2019
2 Reads

[Sleepyhead: neuroscience, narcolepsy and the search for a good night].

Rev Neurol 2019 Jan;68(1):45-46

Hospital General Universitario Gregorio Maranon, Madrid, Espana.

View Article

Download full-text PDF

Source
January 2019
4 Reads

Interplay Between Amphetamine and Activity Level in Gene Networks of the Mouse Striatum.

Bioinform Biol Insights 2018 11;12:1177932218815152. Epub 2018 Dec 11.

Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL, USA.

The psychostimulant amphetamine can be prescribed to ameliorate the symptoms of narcolepsy, attention-deficit hyperactivity disorder and to facilitate weight loss. This stimulant can also have negative effects including toxicity and addiction risk. The impact of amphetamine on gene networks is partially understood and this study addresses this gap in consideration of the physical activity. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1177932218815152
Publisher Site
http://dx.doi.org/10.1177/1177932218815152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291885PMC
December 2018
10 Reads

Narcolepsy, Precocious Puberty and Obesity in the Pediatric Population: a Literature Review.

Pediatr Endocrinol Rev 2018 Dec;16(2):266-274

Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, Brazil, E-mail:

Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis and hypnagogic and hypnopompic hallucinations. The onset of the symptoms usually occurs in childhood, and previous studies have reported an association between narcolepsy and other endocrine diseases in the pediatric population, such as obesity and precocious puberty. The incidence of overweight or obesity ranges from 25% to 74% in patients with narcolepsy type I, while precocious puberty is present in 17% of children with narcolepsy with cataplexy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17458/per.vol16.2018.NarcolepsypubertyobesityDOI Listing
December 2018
1 Read

Identification of new urinary gamma-hydroxybutyric acid markers applying untargeted metabolomics analysis following placebo-controlled administration to humans.

Drug Test Anal 2018 Dec 12. Epub 2018 Dec 12.

Department of Forensic Pharmacology & Toxicology, Zurich Institute of Forensic Medicine, University of Zurich, Switzerland.

Gamma-hydroxybutyrate (GHB) is a short-chain fatty acid that occurs naturally in the mammalian brain and is prescribed as a medication against narcolepsy or used as a drug of abuse. Particularly, its use as a knock-out drug in cases of drug-facilitated crimes is of major importance in forensic toxicology. Because of its rapid metabolism and resulting narrow detection windows (<12 hours in urine), detection of GHB remains challenging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dta.2558DOI Listing
December 2018
1 Read

The neurobiological basis of narcolepsy.

Nat Rev Neurosci 2019 Feb;20(2):83-93

Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.

Narcolepsy is the most common neurological cause of chronic sleepiness. The discovery about 20 years ago that narcolepsy is caused by selective loss of the neurons producing orexins (also known as hypocretins) sparked great advances in the field. Here, we review the current understanding of how orexin neurons regulate sleep-wake behaviour and the consequences of the loss of orexin neurons. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41583-018-0097-xDOI Listing
February 2019
3 Reads

Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy.

Proc Natl Acad Sci U S A 2018 12 12;115(52):E12323-E12332. Epub 2018 Dec 12.

Center for Sleep Sciences and Medicine, Stanford University School of Medicine, Palo Alto, CA 94304;

Type 1 narcolepsy (T1N) is caused by hypocretin/orexin (HCRT) neuronal loss. Association with the HLA DQB1*06:02/DQA1*01:02 (98% vs. 25%) heterodimer (DQ0602), T cell receptors (TCR) and other immune loci suggest autoimmunity but autoantigens are unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1818150116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310865PMC
December 2018
1 Read

A false alarm of narcolepsy: obstructive sleep apnea masquerading as narcolepsy and depression.

Sleep Breath 2018 Dec 6. Epub 2018 Dec 6.

Department of Psychiatry, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Purpose: We report a case with symptoms and signs of obstructive sleep apnea (OSA), depression, and narcolepsy. Polysomnographic (PSG) and multiple sleep latency test (MSLT) findings, clinical characteristics, and diagnostic challenges in this case are discussed.

Methods: A 23-year-old single male presented with excessive daytime sleepiness, low mood, lack of energy, and snoring for 3 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11325-018-1767-7DOI Listing
December 2018
1 Read
2.869 Impact Factor

Narcolepsy, Anesthesia, and Sedation: A Survey of the Perioperative Experience of Patients With Narcolepsy.

Anesth Analg 2018 Dec 11. Epub 2018 Dec 11.

Division of Pulmonary, Critical Care and Sleep Medicine, MetroHealth Medical Center, Cleveland, Ohio.

Background: Patients with narcolepsy may be at increased perioperative risk due to the interactions among anesthesia, narcolepsy, and narcolepsy medications. This study sought to determine the perioperative experience of narcoleptic patients undergoing anesthesia or sedation, the frequency of perioperative counseling, and self-reported surgical complications.

Methods: A 22-question survey was developed by expert consensus and distributed by the Narcolepsy Network. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1213/ANE.0000000000003954DOI Listing
December 2018
1 Read
3.472 Impact Factor

Red Flags for early referral of people with symptoms suggestive of narcolepsy: a report from a national multidisciplinary panel.

Neurol Sci 2018 Dec 12. Epub 2018 Dec 12.

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

Objective: Narcolepsy is a lifelong disease, manifesting with excessive daytime sleepiness and cataplexy, arising between childhood and young adulthood. The diagnosis is typically made after a long delay that burdens the disease severity. The aim of the project, promoted by the "Associazione Italiana Narcolettici e Ipersonni" is to develop Red Flags to detect symptoms for early referral, targeting non-sleep medicine specialists, general practitioners, and pediatricians. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10072-018-3666-xDOI Listing
December 2018
1 Read

Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy.

Nat Commun 2018 12 6;9(1):5229. Epub 2018 Dec 6.

Center for Sleep Science and Medicine, Stanford University, Stanford, 94304, CA, USA.

Analysis of sleep for the diagnosis of sleep disorders such as Type-1 Narcolepsy (T1N) currently requires visual inspection of polysomnography records by trained scoring technicians. Here, we used neural networks in approximately 3,000 normal and abnormal sleep recordings to automate sleep stage scoring, producing a hypnodensity graph-a probability distribution conveying more information than classical hypnograms. Accuracy of sleep stage scoring was validated in 70 subjects assessed by six scorers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-07229-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283836PMC
December 2018
6 Reads

Narcolepsy: Diagnosis and management.

Cleve Clin J Med 2018 12;85(12):959-969

Assistant Professor and Consultant, Department of Neurology and Center for Sleep Medicine, Mayo Clinic, Rochester, MN, USA.

Narcolepsy is a chronic disorder of hypersomnia that can have a significant impact on quality of life and livelihood. However, with appropriate treatment, its symptoms are manageable, and a satisfying personal, social, and professional life can still be enjoyed. Greater awareness of the disorder promotes accurate and efficient diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3949/ccjm.85a.17086DOI Listing
December 2018
2 Reads

T cells fingered as culprits for narcolepsy.

Authors:
Barbara Nasto

Nat Biotechnol 2018 Dec;36(12):1130

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nbt1218-1130DOI Listing
December 2018
1 Read

Disease-specific attention impairment in disorders of chronic excessive daytime sleepiness.

Sleep Med 2019 Jan 15;53:133-140. Epub 2018 Oct 15.

Institute of Sleep Medicine and Neuromuscular Disorders, University Hospital Muenster, Germany. Electronic address:

Objective: Patients with chronic excessive daytime sleepiness (EDS) complain of substantial attention deficits. However, their underlying neuronal dysfunction is largely unknown. Previous studies showed similar attention performances in central disorders of hypersomnolence suggesting that EDS-related cognitive impairment is independent of its cause. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sleep.2018.09.021DOI Listing
January 2019
1 Read

Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.

Sleep Med Rev 2019 02 8;43:23-36. Epub 2018 Nov 8.

Center for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA 94025, USA. Electronic address:

Excessive daytime sleepiness (EDS) and cataplexy are common symptoms of narcolepsy, a sleep disorder associated with the loss of hypocretin/orexin (Hcrt) neurons. Although only a few drugs have received regulatory approval for narcolepsy to date, treatment involves diverse medications that affect multiple biochemical targets and neural circuits. Clinical trials have demonstrated efficacy for the following classes of drugs as narcolepsy treatments: alerting medications (amphetamine, methylphenidate, modafinil/armodafinil, solriamfetol [JZP-110]), antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors), sodium oxybate, and the H-receptor inverse agonist/antagonist pitolisant. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10870792183003
Publisher Site
http://dx.doi.org/10.1016/j.smrv.2018.09.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351197PMC
February 2019
12 Reads